Intraductal papillary or mucinous tumors (IPMT) of the pancreas: report of a case series and review of the literature
- PMID: 11374680
- DOI: 10.1111/j.1572-0241.2001.03689.x
Intraductal papillary or mucinous tumors (IPMT) of the pancreas: report of a case series and review of the literature
Abstract
Objective: Despite a better understanding of these conditions, intraductal papillary or mucinous tumors (IPMT) of the pancreas still present difficulty relating to the predictive factors of malignancy and the risk of relapse after surgical resection. The aim of this study was to report on our experience and to compare it to previously published cases.
Methods: We studied retrospectively 26 patients (mean age 60.3 yr) presenting with IPMT. Of the 26 patients, 19 had surgical resection and seven did not. The main clinical feature was acute pancreatitis occurring in 38% of the patients. Segmental pancreatectomy was performed in all the cases. At pathological assessment of resection margins, tumor resection was considered as complete in 17 cases. Margins exhibited benign mucinous involvement, and resection was considered to be incomplete in one multifocal case and in one case with diffuse spread of the tumor.
Results: A total of 11 tumors were benign and five were malignant. Carcinomas were invasive in four cases (two invading the pancreatic parenchyma, one the duodenum, and one the peripancreatic nodes) and in situ in one case. Malignancy was not diagnosed preoperatively except when invasion was evident (duodenal spread). Although main pancreatic duct type and obstructive jaundice appeared as suggestive features for the risk of malignancy, no reliable preoperative predictive factors for malignancy could be identified as regarding to clinical parameters, biological examinations, carcinoembryonic antigen or CA19-9 levels in serum or in pure pancreatic juice, imaging, and cytological methods. Within 40.8 months mean follow-up after surgery (range 2-96 months), three patients (16%), two with malignant and one with benign tumor, had tumor relapse after respectively 7, 27, and 14 months. Margins were positive without malignant features in the two malignant cases and negative in the other case. Tumor relapse was malignant with diffuse spreading in the three cases, and the patients died within 34 months after surgical resection.
Conclusions: Our series and the review of the literature indicate that preoperative indicators of malignancy in IPMT are still lacking. Concerning resection margins, complete tumor resection is usually possible by segmental pancreatectomy. Malignant relapses are not exceptional. Incomplete resection and diffuse or multifocal tumor represent poor prognostic factors. Total pancreatectomy should be considered in such cases.
Similar articles
-
Outcome after surgical resection of intraductal papillary and mucinous tumors of the pancreas.Am J Gastroenterol. 2000 Feb;95(2):441-5. doi: 10.1111/j.1572-0241.2000.01764.x. Am J Gastroenterol. 2000. PMID: 10685747
-
[Anatomy of the head of the pancreas and various limited resection procedures for intraductal papillary-mucinous tumors of the pancreas].Nihon Geka Gakkai Zasshi. 2003 Jun;104(6):460-70. Nihon Geka Gakkai Zasshi. 2003. PMID: 12854493 Review. Japanese.
-
Clinicopathologic features and outcomes of intraductal papillary-mucinous tumors of the pancreas.Hepatogastroenterology. 2002 Jan-Feb;49(43):263-7. Hepatogastroenterology. 2002. PMID: 11941971
-
Pylorus-preserving total pancreatectomy for an intraductal papillary-mucinous neoplasm of the pancreas.J Hepatobiliary Pancreat Surg. 2007;14(3):264-9. doi: 10.1007/s00534-006-1146-9. Epub 2007 May 29. J Hepatobiliary Pancreat Surg. 2007. PMID: 17520201
-
Biliopancreatic fistula associated with intraductal papillary-mucinous pancreatic cancer: institutional experience and review of the literature.Hepatogastroenterology. 2000 Jul-Aug;47(34):1164-7. Hepatogastroenterology. 2000. PMID: 11020905 Review.
Cited by
-
Predictors of recurrence in intraductal papillary mucinous neoplasm: experience with 183 pancreatic resections.J Gastrointest Surg. 2013 Sep;17(9):1618-26. doi: 10.1007/s11605-013-2242-1. Epub 2013 Jun 28. J Gastrointest Surg. 2013. PMID: 23813047
-
The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer.Int J Gastrointest Cancer. 2002;32(1):1-6. doi: 10.1385/IJGC:32:1:1. Int J Gastrointest Cancer. 2002. PMID: 12630764
-
Malignant potential of intraductal papillary mucinous neoplasms of the pancreas.Surg Today. 2010 Sep;40(9):816-24. doi: 10.1007/s00595-009-4227-y. Epub 2010 Aug 26. Surg Today. 2010. PMID: 20740343 Review.
-
Natural history of intraductal papillary mucinous neoplasms (IPMN): current evidence and implications for management.J Gastrointest Surg. 2008 Apr;12(4):645-50. doi: 10.1007/s11605-007-0447-x. Epub 2007 Dec 19. J Gastrointest Surg. 2008. PMID: 18097728 Review.
-
Natural history of intraductal papillary mucinous neoplasia: How much do we really know?World J Gastrointest Surg. 2010 Oct 27;2(10):368-72. doi: 10.4240/wjgs.v2.i10.368. World J Gastrointest Surg. 2010. PMID: 21160846 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical